SOURCE: Equity News Circuit

Equity News Circuit

May 17, 2013 08:20 ET

Free Research Reports on HOV, IMOS, JACK and ONTY Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 17, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

Hovnanian Enterprises, Inc. (NYSE: HOV) shares declined roughly 2.3 percent on volume of over 5.5 million shares traded Thursday. Homebuilding stocks were dragged down by a report from the Commerce Department that showed U.S. housing starts declined to a seasonally adjusted annual rate of 853,000, a 16.5 percent drop when compared to March.

Find out more about Hovnanian Enterprises including full access to the free equity report at: www.ParagonReport.com/HOV

ChipMOS Technologies (Bermuda) Ltd. (NASDAQ: IMOS) shares hit a new 52-week high of 17.43 a share Thursday after releasing results for the first quarter. The company swung to a net income of $12.2 million, or $0.41 per share, for first quarter, compared to a loss of $5.7 million, or $0.21 per share, a year ago.

Find out more about ChipMOS Technologies including full access to the free equity report at: www.ParagonReport.com/IMOS

Jack in the Box Inc. (NASDAQ: JACK) shares declined roughly 3.5 percent on volume of nearly 1.0 million shares traded Thursday. The fast-food company reported earnings of $13.3 million, or $0.29 per share, for the fiscal second quarter, compared to earnings of $21.6 million, or $0.48 per share, a year ago.

Find out more about Jack in the Box including full access to the free equity report at: www.ParagonReport.com/JACK

Oncothyreon Inc. (NASDAQ: ONTY) shares dropped over 23 percent on volume of more than 4.0 million shares traded Thursday to close at $2.00 a share. The company announced its experimental lung cancer treatment, L-BLP25, did not meet its endpoint of improving overall survival in a recent clinical trial.

Find out more about Oncothyreon including full access to the free equity report at: www.ParagonReport.com/ONTY

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information